Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
Priscilla K. Brastianos, Albert E. Kim, Anita Giobbie‐Hurder, Eudocia Q. Lee, Nancy U. Lin, Beth Overmoyer, Patrick Y. Wen, Lakshmi Nayak, Justine V. Cohen, Jörg Dietrich, April F. Eichler, Rebecca S. Heist, Ian E. Krop, Donald P. Lawrence, Jennifer A. Ligibel, Sara M. Tolaney, Erica L. Mayer, Eric P. Winer, Brittany Bent, Magali de Sauvage, Nazanin Ijad, Juliana M. Larson, Braxton Marion, Sally Nason, Naina Murthy, Sherry Ratcliff, Elizabeth J Summers, Maura Mahar, Helen A. Shih, Kevin Oh, Daniel P. Cahill, Elizabeth R. Gerstner, Ryan J. Sullivan
Topics & Concepts
MedicineClinical endpointPembrolizumabInternal medicineCohortAdverse effectOncologySurgeryClinical trialCancerImmunotherapyBrain Metastases and TreatmentLung Cancer Research StudiesGlioma Diagnosis and Treatment